The antimicrobial susceptibility of Propionibacterium acnes isolated before and after treatment of acne patients was measured. The four female and three male acne patients were treated with an oral acne medication, roxithromycin or minocycline, and/or a topical acne medication, nadifloxacin cream or clindamycin hydrochloride lotion for 1 – 8 weeks. The isolated strains were tested for their susceptibility to the antimicrobial action of: nadifloxacin, ofloxacin, erythromycin, clindamycin hydrochloride, tetracycline hydrochloride, minocycline, doxycycline, ampicillin, cephalexin and gentamycin. No resistant strains of P. acnes were observed.
CunliffeWJ: Pathogenesis of acne. In: Acne. London: Marin Dunitz, 1989; p. 251.
2.
LeydenJJ: New understandings of the pathogenesis of acne. J Am Acad Dermatol1995; 32: S15–S25.
3.
KuwokawaI, NishijimaS, AsadaY: The antibiotic susceptibility of Propionibacterium acnes: A 15-year bacteriological study. J Dermatol (Tokyo)1988; 15: 149–154.
4.
KurokawaI, AkamatsuH, NishijimaS,: Clinical and bacteriologic evaluation of OPC-7251 in patients with acne: A double-blind group comparison study versus cream base. J Am Acad Dermatol1991; 25: 674–681.
5.
KurokawaI, TanakaM, IkedaT: Topical aqua Kummelfeld containing 1% lincomycin for acne vulgaris. J Dermatol Treat1992; 3: 209–211.
6.
AkamatsuH, NishijimaS, TakahashiM: Effects of subminimal inhibitory concentrations of EM, TC, CLDM, MINO on the neutrophil chemotactic factor in Propionibacterium acnes biotype 1-5. J Dermatol (Tokyo)1991; 18: 247–251.
7.
AkamatsuH, NiwaY, KurokawaI: Effects of subminimal inhibitory concentrations of minocycline on neutrophil chemotactic factor production in comedonal bacteria, neutrophil phagocytosis and oxygen metabolism. Arch Dermatol Res1991; 283: 524–528.
8.
Japan Society of Chemotherapy: Revised standardized method for determination of the minimum inhibitory concentrations in bacteria. Chemotherapy1981; 29: 76–79.
9.
EadyEA, BojarRA, JonesCE: The effect of acne treatment with a combination of benzoyl peroxide and erythromycin on skin carriage of erythromycin-resistant Propionibacteria. Br J Dermatol1996; 134: 107–113.
10.
JonesRN, BarryAL, ThornserryC: In vitro evaluation of three new macrolide antimicrobial agents, RU 28965, RU 29065, RU 29702, and comparisons with other orally administered drugs. Antimicrob Agents Chemother1983; 24: 209–215.
11.
BarlamT, NeuHG: In vitro comparison of the activity of RU 28965, a new macrolide, and anaerobic bacteria. Antimicrob Agents Chemother1984; 25: 529–531.
